Business
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
In-depth characterization of CD3-binding antibodies reveals molecules with binding and functional properties that are differentiated from antibodies commonly
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\n\nIn-depth characterization of CD3-binding antibodies reveals molecules with binding and functional properties that are differentiated from antibodies commonly used for T-cell engager development\n\n\n\nDiscovery of antibodies with high specificity for a peptide-MHC complex demonstrates capabilities for development of T-cell engagers against challenging cancer targets\n\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023. AbCellera debuted its TCE platform at AACR 2022 with data describing the diversity of its CD3-binding antibodies. Presentations at AACR 2023 illustrated how AbCellera streamlines the development of TCEs with optimal functional properties for diverse tumor targets.\n\n\n“T-cell engagers are amongst the most promising new modalities in cancer therapy. The robust characterization of our novel CD3-binding antibodies in both mono- and bispecific formats illustrates that we can engineer optimal TCEs by fine-tuning tumor cell killing and cytokine release,” says Bo Barnhart, Ph.D., VP, Translational Research at AbCellera. “Combined with our ability to discover antibodies against some of the most challenging cancer targets, our engine can enable the development of custom-built TCEs for a wide range of cancers.”\n\n\nFirst, AbCellera demonstrated that its panel of novel, fully human CD3-binding antibodies can build optimized TCEs that have functional profiles superior to benchmark molecules. The presentation included:\n\n\n\nA comprehensive data package on a panel of CD3-binding antibodies, including binding and functional comparisons to molecules commonly used for TCE development.\n\n\n\nTwo proof-of-concept studies in which novel CD3-binding antibodies were used to engineer TCEs for different tumor targets. The resulting TCEs included bispecific antibodies with high potencies and low cytokine release in in vitro assays. Differences in T-cell function across tumor targets emphasized the importance of selecting the right CD3- and tumor-binding antibodies for an optimal TCE. These data demonstrate how AbCellera’s novel CD3-binding...